Nephron Research Upgrades Bright Health Gr to Buy, Announces $85 Price Target
Portfolio Pulse from richadhand@benzinga.com
Nephron Research analyst Joshua Raskin has upgraded Bright Health Gr (NYSE:BHG) from Hold to Buy and set a price target of $85.
June 30, 2023 | 2:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bright Health Gr (NYSE:BHG) has been upgraded from Hold to Buy by Nephron Research, with a new price target of $85.
The upgrade from Hold to Buy by Nephron Research indicates a positive outlook for Bright Health Gr. The new price target of $85 suggests a significant upside potential from the current price. This could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100